¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ
¼¶±ð: ³õ¼¶²©ÓÑ
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-04-19   

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ

µÚËľüÒ½´óѧһ¾Å¾Å¶þÄê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧÊÔÌâ ѧ¿Æ×¨Òµ£º Gc2sY 0  
dK'?<w$  
´«È¾²¡Ñ§ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ N"M K 0k  
2GOQ|Z  
Ò». Ãû´Ê½âÊÍ(ÿÌâ4·Ö,¹²32·Ö) V_f}Y8>e  
# D"TY-$.=  
1. ICAM-1 wuE]ju<  
"&?F 6Pi  
2. interleukin 12(IL-12) la#f,C3_  
2|]$hjs  
3. tumor infiltrating lymphocyte Ug>yTc_(7  
Eyi^N0  
4. TCR/CD3 complex %7=B?c |  
usEd p  
5. hematopoietin receptor family %,f|H :+>u  
z =1 J{]  
6. individual idiotype(IdI) [kwVxaI  
QX}O{LQR  
7. integrin ,E,oz{,i(  
?U'c;*O-  
8. colony-stimulatory factor (CSF) @+II@[ _lT  
@IL_  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© l`c&nf6  
d |5V"U]W;  
1. ÃâÒßÇòµ°°×ÖØÁ´µÄ»ùÒòÈçºÎ½øÐÐÀà±ðת»»(class switching )? "@: b'm  
P,5gaT)  
2. ¼òÊöɱÉËÐÔTϸ°û(Tc)ɱÉ˲¡¶¾¸ÐȾ°Ðϸ°ûµÄ»úÀí¡£ Wr+?ul*_  
VZ"W_U,  
3. ÉúÎïÓ¦´ðµ÷½Ú¼Á( biological response modifier,BRM)Ö÷ÒªÓÐÄļ¸Àà?¼òÒª½éÉÜÔÚ´«È¾ÐÔ¼²²¡·ÀÖÎÖеÄ×÷Óᣠ7A0D[?^xe  
,iKEIxA!  
4. ¼òÊö¿¹Ô­Ìá³Êϸ°û(APC)Ó븨ÖúÐÔTϸ°û(Th)Ï໥×÷ÓõĹØÏµ¡£ W*A-CkrO  
H^y%Bi&^  
Èý. ÎÊ´ðÌâ(ÿÌâ18·Ö,¹²36·Ö) On%21L;JG  
g/H:`J  
1. ÊÔÊö¸ÉÈÅËØµÄ·ÖÀ༰ÆäÉúÎïѧ×÷ÓÃÌØµã¡£Ö÷Òª¿ÉÒÔÖÎÁÆÄÄЩ´«È¾ÐÔ¼²²¡?¼òÊö¸ÉÈÅËØ¼ì²âµÄ·½·¨ºÍÔ­Àí¡£ hAx#5@*5  
(!kd9uV  
2. ºÎΪ»ùÒò¹¤³Ì¿¹Ìå?Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? µÚËľüÒ½´óѧһ¾Å¾ÅÈýÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: ÃâÒßѧ Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 1. CD4 2. T cell receptor(TCR) a1V+doC  
7/*Q?ic  
3. immunoglobulin superfamily (IgSF) . ] =$((  
6zuWG0t  
4. selectin Glz)-hjJ:n  
3Z?"M  
5. anti-idiotypic antibody (¦ÁId) *n9t~t6GHg  
8r"$o1!  
6. major histocompatibility complex(MHC) QLNQE6-  
aH@Ux?-}  
7. immunotolerance K/oC+Z;K  
Z}#, E ;  
8. biological reponse modifier(BRM) :e9}k5kdk  
SQ*dC  
9. immune reponse gene (Ir gene) l| 1O9I0Gd  
$dr=M (&  
10. reshaped antibody (or reconstituted antibody) t ;wfp>El  
K$>C*?R  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© x13t@b  
~ Iin|  
1. ¼òÊö°×ϸ°û½éËØ6(IL-6)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¡£ G$X+g{  
M%dJqwH5{  
2. ϸ°û¶¾ÐÔTÁܰÍϸ°û(Tc»òCTL)Ó뿹ÌåÒÀÀµµÄϸ°û½éµ¼µÄϸ°û¶¾(ADCC)ɱÉË»úÀíÓкβ»Í¬? HsA4NRF'7  
;CbQ}k  
3. ¼òÊöµÚ¢ôÐÍ(³Ù·¢ÐÍ)±ä̬·´Ó¦µÄ·¢Éú»úÀí¡£ A`E7V}~  
SM> V o+  
4. NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄ±íÃæ±ê¼Ç?NKϸ°ûÓÐÄÄЩÖ÷ÒªµÄÉúÎïѧ»îÐÔ? 3#)I7FG  
S+c)  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö) ¹©´«È¾²¡Ñ§×¨ÒµÊÔÌ⣺ dP8b\H  
2[WH8l+  
1. »úÌåÓÐÄÄЩÃâÒßϸ°ûºÍÃâÒß·Ö×Ó²ÎÓ뿹²¡¶¾¸ÐȾ?ËüÃÇÊÇÈçºÎ·¢»Ó²¡¶¾ÃâÒß×÷ÓõÄ? yKJKQ9  
r:h\{ DVf  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚ²¡¶¾Ñ§ÖÐÓÐÄÄЩÖ÷ÒªÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ oqzx}?0  
w+ZeVZv!r  
¹©Ïû»¯ÄÚ¿Æ×¨ÒµÊÔÌ⣺ sflH{!;p  
!Pnvqgp/  
1. ĿǰÌåÄÚºÍÌåÍâ¼ì²âÖ×Áö»¼ÕßÃâÒß¹¦Äܵķ½·¨Ö÷ÒªÓÐÄÄЩ?·Ö±ðÐðÊöÿÖÖ·½·¨µÄÔ­ÀíºÍ½á¹û²â¶¨? nic7RN?F<  
9NCo0!Fb  
2. Ŀǰµ¥¿Ë¡¿¹ÌåÔÚÖ×ÁöѧÖÐÓÐÄÄЩÖ÷ÒªµÄÓÃ;?½ñºó¿ÉÄÜÓÐÄÄЩÖ÷ÒªµÄ·¢Õ¹·½Ïò? ¡¡ ImJ2tz6  
A%H"a+  
µÚËľüÒ½´óѧһ¾Å¾ÅËÄÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ѧ¿Æ×¨Òµ: ~Yrtz   
* b+ef  
´«È¾²¡Ñ§¡¢ Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿: %T:~N<8)  
Kyy CS>  
ÃâÒßѧ ] Lg$p  
g70B22!y  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© ]IQTf5n  
xA|72!zk0P  
1. CD8 zZ3Ko3L%g_  
C(i1Vx<-  
2. T cell receptor ¦Á and ¦Â chain (TCR¦Á¦Â ) s;-(dQ{O  
c`]_Q1'30w  
3. immunoglobulin fold(Ig fold) f?O?2 g  
'bN\8t\S  
4. cadherin (Ca-dependent cell adhesion moleculers) mSSDV0Pfn  
R +H0+omj  
5. idiotype-anti-idiotypic antibody immune network theory ,v;P@RL|g  
>5Vv6_CI0?  
6. HLA class II antigen 3D3/\E#'o  
uW*)B_c  
7. complementarity-determining region (CDR) Q[t|+RNKv2  
sqkk 4w1#C  
8. perforin(or pore-forming protein ,PFP) Ew>E]Ys  
4(5NHsvp  
9. high affinity IL-2 receptor  5VWyc9Q  
 Dh=?Hzw  
10. artificial active immunization .W _'6Q+  
#.|ef dsG  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© sJ{S(wpi"  
Opc, {,z6  
1. ¼òÊö°×ϸ°û½éËØ2(IL-2)Ö÷ÒªµÄÉúÎïѧ»îÐÔ¼°ÆäÔÚÁÙ´²ÖÎÁÆÖеÄÓ¦ÓᣠtOx)t$ix  
 /="~Jo  
2. Çë±È½ÏµÚ¢ñÐÍ(ËÙ·¢ÐÍ)³¬Ãô·´Ó¦ÓëµÚ¢ôÐÍ(³Ù·¢ÐÍ)³¬Ãô·´Ó¦µÄ·¢²¡Ìص㡣 #l kv&.)x  
[=dK%7v  
3. ÊÔÊö·ÖÃÚÐÍIgA(secretory IgA)µÄ½á¹¹ÌصãºÍºÏ³É·ÖÃÚ¹ý³Ì¡£ N?]HWP^pg  
i7hWBd4wK  
4. ÊԱȽÏT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(Èç±íÃæ¿¹Ô­¡¢±íÃæÊÜÌåµÈ)µÄÒìͬµã¡£ N#(p_7M  
Z(F`M;1>xI  
Èý. ÎÊ´ðÌâ(ÿÌâ14·Ö,¹²28·Ö¡£Çë×¢Ò⣺ÿλ¿¼ÉúÖ»ÄÜ´Ó1¡¢2ÌâÖÐѡһÌâ,3¡¢4ÌâÖÐѡһÌâ,¹²´ðÁ½Ìâ,¶à´ðÕß²»¼Æ·Ö¡£) 1. Ŀǰ¼ì²âϸ°ûÒò×ÓÖ÷ÒªÓÐÉúÎïѧ»îÐÔ¼ì²â·¨ºÍÃâÒßѧ¼ì²â·¨,Çë¾ÙÀý·Ö±ðÐðÊöÁ½ÖÖ·½·¨µÄʵÑéÔ­Àí¡£ L1'R6W~%dN  
hS<lUG!9UJ  
2. ΪÁ˱ÜÃâIgG¿¹ÌåFc¶Î·ÇÌØÒìÐÔ×÷ÓÃ,³£Ó¦ÓÃθµ°°×øˮ½âµÄF(ab¡¯)2¶Î,ÊÔÎÊÈçºÎÓ¦ÓÃSDS-PAGE·½·¨¶ÔF(ab¡¯)2½øÐмø¶¨? 0Z.b d=H  
Gt >*y.]  
3. ÊÔÊö¿¹Ö×Áö»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ 9"T&P_   
5Oh>rK(  
4. ÊÔÊö¿¹²¡¶¾»ùÒò¹¤³Ì¿¹ÌåµÄÑо¿½øÕ¹¡£ ¡¡ 0E[&:6#Y  
WCf?_\cG  
µÚËľüÒ½´óѧһ¾Å¾ÅÎåÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ W dM?{; #  
~.-o*  
ѧ¿Æ×¨Òµ£ºÃâÒßѧ¡¢´«È¾²¡Ñ§¡¢Ïû»¯ÄÚ¿Æ ¿¼ÊÔ¿ÆÄ¿£ºÃâÒßѧ v#yeiE4  
'Z^-(xG,+  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© qX,T X 3  
.d }7c!  
1. immunoglobulin gene rearrangement Y 6B7qp  
[nL{n bli  
2. the common chain of cytokine receptor (or a cytokine receptor subunit shared by some cytokine receptors) ,OGXH2!h  
Pe-1o#7~W  
3. flow cytometry(FCM) o5k7$0:t/  
V 4~`yT?*"  
4. carrier effect <$H-/~Y  
JerueF;J  
5. positive selection of T lymphocytes in thymus >ZX&2 {  
'fIBJ3s[o  
6. mouse TH1(Th1) and TH2(Th2) subsets (P=q&]l[  
D\"F?>  
7. perforin (pore-forming protein ,PFP) ^)\z  
*Fb|iR  
8. ADCC(antibody-dependent cell-mediated cytotoxicity) VMa \?`fT  
P LH iQ:  
9. SH-2(src-homology region 2) P&3Z,f0  
g`NJ `  
10. Ab2¦Â (internal image) 2.6F5&:($  
k|kn#X3X  
¶þ. ¼ò´ðÌ⣨ÿÌâ8·Ö£¬¹²32·Ö£© 1-!q,q  
.|Ee,Un  
1. ½üÄêÀ´ÔÚÈËÀà°×ϸ°û·Ö»¯¿¹Ô­(CD)Ñо¿ÁìÓòÖÐÓÐÄÄЩÖ÷Òª½øÕ¹? T/9`VB%N  
u)NmjW  
2. ²ÎÓë»î»¯Tϸ°ûÓë»î»¯Bϸ°ûÏ໥×÷ÓõķÖ×ÓÖ÷ÒªÓÐÄÄЩ?¼òÊöÆä½á¹¹ºÍ¹¦ÄÜ? pb`!_GmB  
W.|r=   
3. ÊÔÊöHLAÔÚÁÙ´²ÉϵÄÖ÷ÒªÓ¦Óᣠb@p3iq:  
X3# AYn,  
4. Àý¾ÙÈýÖÖ´ÓÈËÍâÖÜѪµ¥¸öºËϸ°û(PBMC)Öд¿»¯Tϸ°ûµÄ·½·¨,·Ö±ðÐðÊöÆäʵÑéÔ­ÀíºÍÖ÷Òª²Ù×÷²½Öè¡£ MPS{MGVjbJ  
0q4E^}iR  
5. ÆÀ¼Ûºìϸ°ûÉú³ÉËØ(EPO)¡¢¸ÉÈÅËØ(IFN)ºÍ¼¯Âä´Ì¼¤Òò×Ó(CSF)ÔÚÁÙ´²Ä³Ð©¼²²¡µÄÓ¦Óᣠ\R}`S`fIw`  
1kDr;.m%  
Èý. Ñ¡ÔñÎÊ´ðÌâ(ÿÌâ10·Ö,¹²20·Ö¡£Çë°´±¨¿¼×¨Òµ´ðÌâ,Èç´ð·Ç±¾×¨ÒµÌâ»ò¶à´ðÌâ¾ùÊÓΪÎÞЧ¡£) /a 'cP  
4fuK pLA  
ÃâÒßѧרҵ£º &IZthJqV  
 ~ [wh  
1. ÊÔÊöϸ°ûÒò×ÓÊÜÌåÖÐ,Ig³¬¼Ò×å¡¢ÔìѪÒò×ÓÊÜÌ峬¼Ò×å¡¢Éñ¾­Éú³¤Òò×ÓÊÜÌ峬¼Ò×åÒÔ¼°Ç÷»¯Òò×ÓÊÜÌ峬¼Ò×åµÄÖ÷Òª½á¹¹Ìصã,ÿ¸ö³¬¼Ò×åÀý¾Ù³ö2¸ö³ÉÔ±¡£ 76'vsg  
a ,EApUWw  
2. ÊԱȽÏÈËT¡¢BÁܰÍϸ°ûϸ°ûĤ±íÃæ·Ö×Ó(±íÃæ±ê¼Ç)µÄÒìͬµã,ËüÃÇ·Ö±ð²ÎÓëÄÄЩÖ÷ÒªµÄÃâÒß¹¦ÄÜ? 0P%,1M3d  
*  11|P  
´«È¾²¡Ñ§×¨Òµ£º Q+r8qnL'  
0}:wM':G  
1. ÈËÀàÃâÒßȱÏݲ¡¶¾(HIV)¸ÐȾÈËÌåºó,ÃâÒß¹¦Äܿɷ¢ÉúÄÄЩÖ÷ÒªµÄ±ä»¯?»úÀíÊÇʲô?ÈçºÎ½øÐÐÏàÓ¦µÄÃâÒßѧ¹¦Äܼì²â£¿ @An "ClDa  
MT?;9ZV}  
2. ÇëÆÀÊöÉö×ÛºÏÕ÷³öѪÈȲ¡¶¾(HFRSV)¸ÐȾºó»úÌåÃâÒßѧ±ä»¯µÄÓ벡ÀíËðÉ˵ĹØÏµ¡£ ophQdJM  
|IgH0 zZ  
Ïû»¯×¨Òµ£º yn;sd+:z  
~"t33U6  
1.ÊÔÊöÓëÏû»¯ÏµÍ³ÓйصÄÖ×ÁöÏà¹Ø¿¹Ô­Ñо¿µÄ½øÕ¹¡£ bq}hj Cy  
?)2&L Vrf  
2.¼òÊöճĤÏà¹ØÁܰÍÑù×éÖ¯(mucosal assiociated lymphoid tissue,MALT)µÄ×é³ÉºÍ¹¦ÄÜÌØµã¡£·ÖÃÚÐÍIgAÊÇÈçºÎ½øÐкϳɺͷÖÃÚµÄ? |J_kS90=  
sC^9  
µÚËľüÒ½´óѧһ¾Å¾ÅÁùÄê¹¥¶Á²©Ê¿Ñ§Î»Èëѧ¿¼ÊÔÊÔÌâ ÃâÒßѧÊÔÌâ o`EL)K{  
GK>.R<[  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© 'T_Vm% \)  
*It`<F|  
1. Fas(CD95)/FasL b5Sgf'B^  
$Qc`4x;N  
2. common chain of cytokine receptor zdh&,!] F6  
YR\pt8(z?  
3 . TCR/CD3 complex m%[Ul@!V  
wQnW2)9!  
4. negaive selection of thymocytes 42If/N?  
2/coa+Qkv]  
5. artificial active immune ;hcOD4or  
 6[{|'  
6. anti-idiotypic ,{tK{XpS  
^#Ruw?D  
7. IgSF /Mg$t6vM  
c-dOb.v0  
8. Integrin tzKIi_2  
K< ;I*cA X  
9. chemokine |v[0(  
tt=JvI9>  
10. B7/CD28 `wzb}"gLsM  
Kpx(x0^2  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²60·Ö£© )nI}KQJ<  
1F*3K3T {  
1. ±È½ÏMHC¢ñºÍMHC¢òÀ࿹ԭ²ÎÓëµÄ¼Ó¹¤Ìá³Ê¿¹Ô­µÄ¹ý³Ì¡£ Vo@gxC,  
`o;E  
2. ±È½ÏCTLºÍNKɱÉ˰Ðϸ°ûʱʶ±ðºÍɱÉË»úÖÆµÄÌØµã¡£ _3_kvs  
ev$\Ns^g$3  
3. ±È½ÏÃâÒßѧ¼ì²â·¨ºÍÉúÎïѧ»îÐÔ¼ì²â·¨¼ì²âϸ°ûÒò×ÓµÄÓÅȱµã¡£ M`~U H\  
sFvu@Wm'7W  
4. ·¢ÏÖÒ»ÖÖеİ×ϸ°û·Ö»¯¿¹Ô­»òÖ×ÁöÏà¹Ø¿¹Ô­,²¢ÖƱ¸Á˵¥¿Ë¡¿¹Ìå,ÊÔÉè¼ÆÊµÑé·½°¸¿Ë¡´Ë»ùÒò¡£ )Td;2  
ry2ZVIFa  
5. Ñ¡ÔñÏÂÊöÖÐÒ»¸öרÌâ,ÐðÊöÎÒ¹úÔÚÕâÒ»Ñо¿ÁìÓòµÄÏÖ×´¼°ÃæÁÙµÄÌôÕ½1)Ö×ÁöÃâÒߣ»(2)»ùÒòÖÎÁÆ£»(3)CD¿¹Ô­¡£ 8H%-/2NW  
 3 )bC,  
µÚËľüÒ½´óѧһ¾Å¾ÅÆßÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÃâÒßѧÊÔÌâ Exy|^Dr0  
gE_i#=bw  
Ò». Ãû´Ê½âÊÍ£¨Ã¿Ìâ4·Ö£¬¹²40·Ö£© vzr?#FG  
S1!X;PP/  
1. B7/CD28 ^~iFG+g5  
T@S\:P  
2. Th1 subset Al 0 i{.V  
=`1#f QDt  
3. seven predicated transmembrane domain receptor superfamily£¨STR superfamily£© aR2Vvo  
MPtn$@  
4. antibody affinity maturation ' 1jG?D  
r&MHww1i  
5. AP-1 S~ff<A>f  
3p %B  
6. single chain variable fragment£¨ScFv£© 4dB6 cg  
5Dhpcgq<<  
7. NK cell receptor `2B,+ytW8  
`ZC{<eVJ}=  
8. Zinkernagel-Doherty phenomenon #lf3$Tm D  
{DI`HB[  
9. Ig fold l\?HeVk^  
&?#,rEw<x  
10. CD40/CD40L cIm_~HH  
gG 9e.++:  
¶þ. ÎÊ´ðÌ⣨ÿÌâ12·Ö£¬¹²36·Ö£© tfSY(cXg'T  
`YK2hr  
1. ÊÔÊöÐØÏÙ΢»·¾³¶ÔÐØÏÙϸ°ûµÄÑ¡Ôñ×÷Óü°ÆäÓëTϸ°û¹¦ÄÜÐÔÑÇȺÐγɵĹØÏµ¡£ ' T '&OA  
R>r@I_  
2. ÊÔÊöÌåÒºÃâÒßÓ¦´ðµÄ¹æÂÉ£¬»ØÒä·´Ó¦ºÍ¿¹ÌåÀà±ðת»»µÄ»úÖÆÊÇʲô£¿ gH0' Ok'  
wc&`/'<p  
3. ÊԴӽṹºÍ¹¦ÄܵȽǶȣ¬²ûÊö°×ϸ°û·Ö»¯¿¹Ô­£¨CD£©¡¢Õ³¸½·Ö×Ó£¨integrin£©ºÍÃâÒßÇòµ°°×³¬¼Ò×壨IgSF£©ÈýÀà·Ö×ÓµÄÏ໥¹ØÏµ¡£Ä¿Ç°ÔÚÕâÒ»ÁìÓòÖÐÖ÷ÒªÑо¿ÈȵãÊÇʲô£¿  c"pI+Q  
,t2yw  
Èý. ÎÊ´ðÌ⣨24·Ö£¬µÚ1ÌâΪÃâÒßѧרҵ¿¼ÉúÊÔÌ⣬µÚ2ÌâΪѪҺ²¡Ñ§¿Æ¿¼ÉúÊÔÌ⣬µÚ3ÌâΪÏû»¯ÄÚ¿Æ¿¼ÉúÊÔÌ⣬ֻÔÊÐí´ð±¾×¨ÒµÊÔÌ⣩ @scy v@5)F  
pd3=^ Zi  
1. ÊԱȽÏTCRºÍBCR½á¹¹¼°Æäʶ±ð¿¹Ô­¡¢ÁܰÍϸ°û»î»¯ÐźŵķÖ×Ó»úÀí¡££¨ÃâÒßѧרҵ£©¡£ xla64Qld  
{.D^2mj |  
2. ÊÔÊö°×Ѫ²¡ÃâÒßѧ·ÖÐÍÀíÂۺͷ½·¨µÄÑо¿½øÕ¹¡££¨ÑªÒº²¡Ñ§×¨Òµ£©¡£ %gd {u\h^  
yFD3:;}  
3. ÊÔÊöÖ×ÁöÒßÃçµÄÑо¿½øÕ¹¡££¨Ïû»¯ÄÚ¿Æ×¨Òµ£©¡£ x)wlp{rLf  
j,]KidDWm  
Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ £¨ÃâÒßѧרҵºÍרҵ»ù´¡£© JQo"<<[  
W N5`zD$  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© q& :UP  
dGNg[  
1.Co-stimulators (or co-stimulating molecules) y7x&/2  
(oftq!X2  
2.NK-kB xT]|78h$   
BE#s@-zR=p  
3.Immunoglobulin superfamily aJ4y%Gy?  
U= Gw(  
4.antigen-presenting cell (APC) &| d6  
*ommU(r8  
5.death domain 7,.3'cCL^  
y<h~jz#hkq  
6.CCR and CXCR ; qQ* p  
hB !>*AsG  
7.Lectin (or mitogen) c=^A3[AM  
60iMfc T  
8.Clusters of differentiation, CD) 0m,3''Q5lO  
MYmH?A  
9.B7 family `veq /!  
#},4m  
10.Cytotoxic T lymphocyte, CTL) "u H VX|`  
\i2S'AblYq  
11.IL-15 and IL-15 receptor (IL-15R) q[wVC h  
@[s+5_9nk  
12.MHC restriction Z ZMz0^V  
Yu`KHvur  
13.Affinity-chromatography FEF $4)ROv  
` 465 H  
14.Cyctosprin A, CsA d,"6s=4(q  
N!TC}#}l  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) l>J>?b=x"[  
[8Yoz1(smA  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© zG|#__= T  
QrX 5Kwq  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 f\zu7,GU  
^p2 _p9  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ v!~ ;Q O  
aOOkC&%  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ "lT>V)NB'  
kzb%=EI  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© v< Ozr:lL  
Vi5&%/Y  
ÃâÒßѧרҵ£º UD+r{s/%  
]rY3bG'&  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ iDdmr32E  
~t,-y*=  
Ïû»¯ÄÚ¿Æ£º 2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ N+V_[qr#  
X^% E"{!nU  
ѪҺ²¡Ñ§×¨Òµ£º 3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿ JKMcdD?'  
(e~vrSk+)~  
Ò»¾Å¾ÅÄê¾Å²©Ê¿ÉúÈëѧ¿¼ÊÔÊÔÌâ (רҵ»ù´¡: ÃâÒßѧ) 6tDCaB  
$1ZF kw  
Ò».Ãû´Ê½âÊÍ(ÿÌâ5·Ö,¹²45·Ö) /Sn>{ &  
)h&*b9[B=  
1. ADCC(antibody dependent cell-mediated cytotoxicity) `(dRb  
G#(+p|n  
2. »·æß¾úËØ(cyclosporin) 1oVjx_I5y  
d$O)k+j  
3. KIR(killer cell inhibitory receptor) XY*KWO  
OBBEsD/bc  
4. HLDA(human leucocyte differentiation antigen) ^;xO-;q  
KJ]ejb$  
5. Interleukin 18(IL-18) xn`<g|"#  
o@!!I w  
6. ÕûºÏËØ(integrin) `& (Fy  
yS2[V,vS7  
7. Fas/FasL N:yyDeGyW  
pSml+A:  
8. FcR(ÃâÒßÇòµ°°×Fc¶ÎÊÜÌå) 4[$D3,A  
{ +.ai8  
9. ϸ°û¼äÕ³¸½·Ö×Ó(ICAM) OlJkyL8|  
n!>#o 1Qr  
10. Th1/Th2 B<A=U r  
W2CQk  
11. »ùÒòÒßÃç(DNAÒßÃç) N!hS`<}  
o D=6D9c?  
12. chemokines and chemokine receptor uSRvc0R\  
y,OwO4+y\  
13. ÃâÒßÄÍÊÜ ^^{gn3xJ  
nG dEJ  
14. ¹²´Ì¼¤·Ö×Ó [Tq\K ^!^  
YhzDi>hob  
15. ËÀÍö½á¹¹Óò(death domain) ONkHHyT  
\B<A.,i4  
¶þ.ÎÊ´ðÌâ(µÚ1¡¢2Ìâ¸÷18·Ö,µÚ3Ìâ19·Ö) JnT1-=t.  
p 7YfOUo k  
1. ÊԱȽÏɱÉËÐÔTϸ°û(CTL)Óë×ÔȻɱÉËϸ°û(NK)ÔÚɱÉ˰Ðϸ°û¹ý³ÌÖÐ,ʶ±ðϸ°û¶¾¼°½éµ¼ÃâÒß¹¦ÄÜÓкβ»Í¬? %N, P? ,U  
^z^ UFW  
2. 70Äê´úÒÔÀ´,ÓйØIgºÍÌåÒºÃâÒßÑо¿´æÔÚÒÔϼ¸ÏîÖØ´ó·¢ÏÖºÍÍ»ÆÆ¶ø»ñµÃҽѧºÍÉúÎïѧŵ±´¶û½±,Çë·Ö±ð²ûÊöËüÃǵÄÀíÂÛÒâÒå¼°ÔÚҽѧʵ¼ùÖеÄÓ¦Óᣠf/&k $, w  
D}| 30s?u1  
£¨1£©1972Ä꣺θµ°°×øºÍľ¹Ïµ°°×øˮ½âIg£¬»ñµÃFab¡¢Fc¡¢F£¨ab¡¯£©2µÈƬ¶Î xzRs ;AXOp  
%j[DG_  
£¨2£©1977Ä꣺·ÅÉäÃâÒß·¨ )/:&i<Q:  
U/|H%b  
£¨3£©1984Ä꣺ÁܰÍϸ°ûÔÓ½»ÁöºÍµ¥¿Ë¡¿¹Ìå SuHv{u45  
P 3CzX48^  
£¨4£©1987Äê: Ig»ùÒòµÄ½á¹¹ 3. ½üÄêÀ´ÔÚÖ×ÁöÃâÒßÑо¿ÁìÓòÖÐÓÐÄÄÐ©ÖØÒª½øÕ¹?ÊÔÊöµ±Ç°Ìá¸ß»úÌ忹Ö×ÁöÃâÒßµÄÖ÷Òª²ßÂÔ¡£ WG_20Jd JY  
eqL~h1^Co  
Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(ÃâÒßѧרҵ) ÎÊ´ðÌâ(ÿÌâ25·Ö) --~m{qmy  
zMXlLRC0  
1. ÊԱȽÏTϸ°ûÊÜÌ壨TCR£©¡¢Bϸ°ûÊÜÌ壨BCR£©ºÍNKϸ°ûÊÜÌ壨NKCR£©µÄ×é³É£¬Ê¶±ðÅäÌåÒÔ¼°ÐźÅתµ¼µÄÒìͬµã¡£ \ :*<En0  
{c3u!} mW  
2. ÒÔÐØÏÙÒÀÀµ¿¹Ô­´Ì¼¤»úÌå²úÉú¿¹ÌåµÄÃâÒßÓ¦´ðΪÀý£¬Tϸ°ûºÍBϸ°ûÊÇÈçºÎÏ໥×÷Óã¿ÓÐÄÄЩճ¸½·Ö×Ӻ͹²´Ì¼¤·Ö×Ó²ÎÓëT¡¢Bϸ°ûµÄÏ໥×÷Óã¿ W:8*Z8?7  
Pw"o[8  
3. Éö×ÛºÏÕ÷³öѪÈÈ(HFRS)²¡¶¾µÄ½á¹¹»ùÒòÒѾ­¸ãÇå³þ,ΪÁË֤ʵHFRS²¡¶¾¸ÐȾ»úÌå(ÒÔBalb/CСÊóΪÀý)¿É²úÉúHFRS²¡¶¾ºËÒ¿ǵ°°×(NP)ÌØÒìÐÔCTL,²¢ÔÚÃâÒß·À»¤ÖÐÆðÖØÒª×÷ÓÃ,ÇëÓ¦ÓÃÃâÒßѧÀíÂۺͷ½·¨,Éè¼ÆÒ»ÏµÍ³ÊµÑé,¼ÓÒÔ֤ʵ¡£ 4. Àý¾Ù¶þ¸ö½üÄêÀ´Ï¸°ûºÍ·Ö×ÓÃâÒßѧÑо¿ÖгöÏÖµÄеÄÈȵã,Çë·Ö±ðÆÀÊöÆäÑо¿ÒâÒå¡¢·¢Õ¹Ç÷ÊÆÒÔ¼°Ó¦ÓÃǰ¾°¡£
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
2+6=? ÕýÈ·´ð°¸:8
°´"Ctrl+Enter"Ö±½ÓÌá½»